Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.

about

Synergistic effects of combining proteasome inhibitors with chemotherapeutic drugs in lung cancer cells.

Item

http://www.wikidata.org/entity/Q44006947

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

Synergistic effects of combini ...... ic drugs in lung cancer cells.

@en

Synergistic effects of combini ...... ic drugs in lung cancer cells.

@nl

type

Item

label

Synergistic effects of combini ...... ic drugs in lung cancer cells.

@en

Synergistic effects of combini ...... ic drugs in lung cancer cells.

@nl

prefLabel

Synergistic effects of combini ...... ic drugs in lung cancer cells.

@en

Synergistic effects of combini ...... ic drugs in lung cancer cells.

@nl

P1476

Synergistic effects of combini ...... ic drugs in lung cancer cells.

@en

P2093

Joachim Gullbo

http://www.w3.org/2001/XMLSchema#string

Johan Lennartsson

http://www.w3.org/2001/XMLSchema#string

Linda Sooman

http://www.w3.org/2001/XMLSchema#string

Michael Bergqvist

http://www.w3.org/2001/XMLSchema#string

Simon Ekman

http://www.w3.org/2001/XMLSchema#string

Stefan Bergström

http://www.w3.org/2001/XMLSchema#string

P2860

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy.

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma

Proteasome inhibitor PS-341 induces apoptosis in cisplatin-resistant squamous cell carcinoma cells by induction of Noxa

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer

Drug combination studies and their synergy quantification using the Chou-Talalay method

Proteasome inhibition sensitizes non-small-cell lung cancer to gemcitabine-induced apoptosis.

A phase 2 study of bortezomib in relapsed, refractory myeloma.

Bortezomib plus gemcitabine/carboplatin as first-line treatment of advanced non-small cell lung cancer: a phase II Southwest Oncology Group Study (S0339)

P2888

s13104-017-2842-z

P304

544

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1186/S13104-017-2842-Z

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P6179

1092508579

http://www.w3.org/2001/XMLSchema#string

P698

29096687

http://www.w3.org/2001/XMLSchema#string

P921

chemotherapy

P932

5667477

http://www.w3.org/2001/XMLSchema#string